Analyst Activity – Maxim Group Reiterates Buy on Galmed Pharmaceuticals (NASDAQ:GLMD)

ME Staff
-
0

Analyst Ratings For Galmed Pharmaceuticals (NASDAQ:GLMD)

Today, Maxim Group reiterated its Buy rating on Galmed Pharmaceuticals (NASDAQ:GLMD) with a price target of $14.00.

There are 3 buy ratings on the stock.

The current consensus rating on Galmed Pharmaceuticals (NASDAQ:GLMD) is Buy (Score: 3.00) with a consensus target price of $15.33 per share, a potential 117.49% upside.

Some recent analyst ratings include

  • 7/31/2017-Maxim Group Reiterated Rating of Buy .
  • 7/6/2016-Roth Capital Reiterated Rating of Buy.
  • 8/19/2015-MLV & Co. Reiterated Rating of Buy.


    Recent Trading Activity for Galmed Pharmaceuticals (NASDAQ:GLMD)
    Shares of Galmed Pharmaceuticals closed the previous trading session at 7.05 down -0.74 -9.50% with 41,298 shares trading hands.